Allergan, Tribe Want PTAB Immunity Denial Reheard En Banc
Law360 (August 20, 2018, 9:59 PM EDT) -- The Saint Regis Mohawk Tribe and Allergan PLC on Friday asked the Federal Circuit court to reconsider en banc its ruling last month that tribal sovereign immunity doesn’t apply in reviews at the Patent Trial and Appeal Board, which rejected the drugmaker’s attempt to shield patents for its dry-eye medication Restasis by transferring them to the Native American tribe.
The drugmaker and the tribe said that the Federal Circuit’s decision cuts against several precedential decisions, and that the case presents an important question as to whether sovereign immunity can be used in inter partes reviews.
“The panel’s reasoning effectively forecloses IPR...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!